CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Pentasa 500 mg capsule x 2 with 240 mL water; single dose +3 moredrug
Likely dose
Pentasa 500 mg capsule x 2 with 240 mL water; single dosefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01999400
NCT01999400N/ACompleted

Correlation of Mesalamine Pharmacokinetics With Local Availability

University of Michigan·interventional·Posted Dec 3, 2013·Updated May 15, 2017

In Brief

A clinical study evaluating Pentasa 500 mg capsule x 2 with 240 mL water; single dose, Apriso 375 mg capsule x 3 with 240 mL water; single dose, and 2 other interventions for Local Drug Concentration in Gastrointestinal Tract. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study is designed to provide data to the FDA correlating pharmacokinetics with local availability of medications within the gastrointestinal tract. This study will support the establishment of scientifically based standards for evaluating drugs which act locally within the gastrointestinal tract. Specific objectives of this study are to: (1) quantify how the plasma concentrations of mesalamine, an agent used to treat inflammatory bowel disease, are correlated with the concentrations in gastrointestinal fluids; and (2) improve the physiologically based models for drug absorption from the intestine. Information from this study in concert with in vitro dissolution data will be used to evaluate in vivo-in vitro correlation (IVIVC) for concentrations in plasma and intestinal lumen and dissolution of mesalamine products.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2013
Enrollment StartApr 1, 2012
Primary CompletionSep 1, 2015
Study CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 12.6 years ago

Interventions

Pentasa 500 mg capsule x 2 with 240 mL water; single dosedrug

Apriso 375 mg capsule x 3 with 240 mL water; single dosedrug

Lialda 1200 mg tablet x 1 with 240 mL water; single dosedrug

Delzicol 100 mg mesalamine x 1 with 245 mL water; single dosedrug